![]() |
市场调查报告书
商品编码
1348456
静脉内空气滤净器全球市场:规模,占有率,趋势分析(2024年~2030年):MedCoreIntravenous Filter Market Size, Share & Trends Analysis | Global | 2024-2030 | MedCore |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
2023年,全球静脉过滤器市场规模为1.593亿美元,较2022年的1.517亿美元成长5.0%。展望未来,预计复合年增长率 (CAGR) 为 4.2%,最终达到 2.127 亿美元。目前,全球静脉过滤器市场由 Pall 公司、GVS、ITW Filtertek 等公司主导。
医疗保健产业越来越认识到静脉治疗中病人安全的重要性。在全球范围内,监管机构和医疗保健组织越来越注重维持病患照护的最高标准。为了满足这些严格的标准,医疗保健提供者必须遵守美国食品药物管理局 (FDA) 和欧洲药品管理局 (EMA) 等知名机构制定的指南和法规。这些监管机构在促进静脉过滤器作为标准医疗方案的组成部分的广泛使用方面发挥着至关重要的作用。透过确保遵守这些准则,医疗保健提供者可以自信地确保患者健康并维持最高品质的照护。
颇尔公司是全球静脉过滤器市场的领导者,并享有重要的市场占有率。该公司的大部分输液过滤器作为 OEM 设备透过输液器和输液帮浦的主要供应商销售。颇尔公司的产品系列包括孔径0.2μm和1.2μm的过滤器,着名的Supor(R)品牌也被静脉输液器市场的领先竞争对手所采用。
GVS 在全球输液过滤器市场中排名第二。该公司主要作为过滤器的 OEM 运营,然后由其他主要 IV 设备製造商销售。GVS 提供多种液体滴滤器选择,以满足各种过滤要求,其中包括 Speedflow 品牌,其过滤器孔径为 0.2、1.2 和 5.0 微米。
ITW Filtertek 专门为其他 OEM 製造作为整合部件的线上过滤器。该公司的产品线包括设计用于静脉给药、全身肠外营养 (TPN)、输血和水注射的过滤器。该公司提供与各种标准孔径过滤器和管道的整合选项。
本报告提供全球静脉内过滤器市场相关调查,提供市场概要,以及各市场区隔,各地区趋势,竞争情形等资讯。
In 2023, the worldwide intravenous filter market exhibited a total worth of $159.3 million, marking a 5.0% upturn from the $151.7 million recorded in 2022. Projections for the upcoming period indicate a steady growth trajectory, with a compound annual growth rate (CAGR) of 4.2%, ultimately reaching $212.7 million. Presently, the global intravenous filter market is under the dominance of Pall Corporation, GVS, and ITW Filtertek.
Our comprehensive medical market research encompassed an extensive analysis of more than 10 intravenous filter companies across seven continents. Employing a rigorous methodology, we delved into market sizes, unit sales, company market shares, and generated precise forecasts.
The healthcare industry is increasingly acknowledging the paramount significance of patient safety throughout intravenous (IV) therapy. Globally, regulatory authorities and healthcare institutions are placing growing emphasis on maintaining the highest standards of patient care. To meet these stringent standards, healthcare providers are required to adhere to guidelines and regulations established by renowned organizations such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). These regulatory bodies play a pivotal role in driving the widespread adoption of IV filters as an essential component of standard healthcare protocols. By steadfastly adhering to these guidelines, healthcare providers can confidently ensure the well-being of their patients and uphold the highest quality of care.
Pall Corporation stands as the frontrunner in the global IV filter market, boasting a substantial market share. The majority of its IV filters are distributed as original equipment manufacturer (OEM) devices through prominent suppliers of IV sets and IV pumps. Pall Corporation's product range encompasses filters with pore sizes of 0.2 and 1.2 micrometers, including the renowned Supor® brand, which is also employed by major competitors in the IV set market.
Securing the second position in the global IV filtration market is GVS. This company primarily operates as an OEM for filters, which are subsequently marketed and sold by other leading suppliers of IV devices. GVS offers a diverse selection of liquid IV filters, including the Speedflow brand, featuring filters with pore sizes of 0.2, 1.2, and 5.0 micrometers to cater to various filtration requirements.
ITW Filtertek specializes in producing in-line filters as integral components for other OEMs. Its product line encompasses filters designed for drug administration through infusion, total parenteral nutrition (TPN), blood transfusion, and aqueous solution infusions. The company offers a range of filters with different standard pore sizes and integration options with tubing.